Its unique mechanism of action, targeting GLP-1, GIP, and glucagon receptors, allows it to effectively regulate appetite and energy expenditure, leading to substantial weight loss
A clinician sees a pattern in their own patients
We can't stress this enough: your data is only as good as your protocol
In March 2022, Novo Nordisk provided updated Ozempic gallbladder warnings about the risk of gallbladder disease, but failed to add information about the risk of gastroparesis or stomach paralysis from Ozempic
Over time, this chronic stimulation drove abnormal growth patterns
The recognition of Habener, Mojsov, and Knudsen by the Lasker~DeBakey Award reinforces the idea that foundational scientific research can lead to transformative clinical applications that improve population health